AI Science Tracker

MRC Epidemiology Unit, University of Cambridge

1 discovery from 2024

Discoveries

Machine learning identifies plasma protein signatures that predict onset of common and rare diseases

Researchers used regularized machine-learning models to select sparse plasma-protein signatures for 10-year incidence across 218 diseases in 41,931 UK Biobank Pharma Proteomics Project participants. Five to twenty proteins improved held-out risk prediction over basic clinical information for 67 diseases and over clinical information plus routine assays for 52. The study identified TNFRSF17 as a specific predictor for future multiple myeloma and TNFRSF13B for monoclonal gammopathy of undetermined significance. In bone-marrow single-cell data from 11 newly diagnosed myeloma patients and three controls, four of five myeloma predictor proteins were most highly expressed by plasma cells; FCRLB and QPCT elevation was attributable to malignant plasma cells. Proteomic signatures also replicated improved prediction for five of six diseases tested in EPIC-Norfolk.

Technology: LASSO feature selection and regularized Cox machine-learning models integrating plasma proteomics and clinical covariates

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Five to twenty proteins improved held-out risk prediction over basic clinical information for 67 diseases and over clinical information plus routine assays for 52.
  • Still unknown: The disease predictions are observational risk associations, not causal mechanisms or clinical screening outcomes. Most protein signatures were not externally replicated; EPIC-Norfolk tested six diseases, with improved prediction replicated for five. The myeloma single-cell analysis involved 11 patients and three healthy controls and supports cellular expression attribution, not prospective validation of an assay. Absolute quantification with clinical-grade assays and further validation would be needed before clinical use.
  • AI role: The authors applied a three-stage machine-learning framework—feature selection, hyperparameter tuning and held-out validation—to ~2,923 proteins in UK Biobank. It selected parsimonious protein signatures for 218 future disease outcomes and identified disease-specific predictors and shared predictors. For multiple myeloma, the model-selected five-protein signature and follow-up single-cell expression analysis linked four predictors to marrow plasma cells and showed malignant-cell-associated FCRLB and QPCT expression.

Evidence sources: https://www.nature.com/articles/s41591-024-03142-z

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 273 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.